<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00581620</url>
  </required_header>
  <id_info>
    <org_study_id>0887X-100974</org_study_id>
    <nct_id>NCT00581620</nct_id>
  </id_info>
  <brief_title>Study Evaluating Prevenar Immunogenicity in High Risk Children</brief_title>
  <official_title>To Evaluate the Humoral Immune Response to a Conjugated Pneumococcus Vaccine 7-Valent (Prevenar®) in Children From High Risk Groups.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine immunogenicity of the heptavalent CRM197 pneumococcal conjugate in children with
      immunodeficiency condition. To evaluate tolerability of Prevenar® in that population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will require 24 months to be completed. Each child will participate for a period
      of time according to age of the 1st dose of vaccination: infants up to 6 months of age will
      be evaluated for 5 months; infants between 7 to 11 months will be evaluated for 3 months;
      children between 12 months up to 9 years of age will be evaluate for 2 months
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine immunogenicity of the heptavalent CRM197 pneumococcal conjugate in children with immunodeficiency condition</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate tolerability of Prevenar* in that population.</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Vaccines, Pneumococcal Conjugate Vaccine</condition>
  <arm_group>
    <arm_group_label>G1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>G1: HIV+</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>G2: Sicle Cell disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>G3: neprotic symdrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>G4: Chronic pulmonary disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pneumococcus conjugate vaccine</intervention_name>
    <description>Infants from 1 to 6 months: 3 doses at 2; 4; 6 m and booster from 12 to 15 months.</description>
    <arm_group_label>G1</arm_group_label>
    <arm_group_label>G2</arm_group_label>
    <arm_group_label>G3</arm_group_label>
    <arm_group_label>G4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children between 2 months to 9 years old.

          -  Children with HIV+; Sickle Cell disease; Neprotic symdrome; Chronic pulmonary disease

          -  No history of seizures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2007</study_first_posted>
  <last_update_submitted>December 21, 2007</last_update_submitted>
  <last_update_submitted_qc>December 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 27, 2007</last_update_posted>
  <responsible_party>
    <name_title>Wyeth (Registry Contact: Clinical Trial Registry Specialist)</name_title>
    <organization>Wyeth</organization>
  </responsible_party>
  <keyword>pneumococcus conjugated vaccine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

